The Medicines Company

Medicines Company goes on the hunt for heartening Orion data

The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.

Alnylam touts givosiran win despite toxicity fears

Alnylam looks likely to get approval for its second RNAi candidate, givosiran. But toxicity issues have tainted the Envision trial win.

January 08, 2019

JP Morgan 2019 – Alnylam turns Onpattro frown upside-down

Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.

April 04, 2018

Therapy focus – Pfizer blows hereditary amyloidosis fight open

March 10, 2018

ACC – Praluent’s Odyssey ends with a whimper

March 07, 2018

No reason for partners to jump into Esperion just yet

January 15, 2018

Event – PCSK9 Odyssey nears its Ithaca

January 10, 2018

M&A: 2017 proves snooze-worthy on the acquisition front

Pharma and biotech takeover activity slumps to a five-year low in 2017.

November 30, 2017

Medicines Company shows that there’s money in antibiotics after all

November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

August 29, 2017

ESC 2017 – Medicines Company forges on alone

Load More